×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Shopping
Maps
Videos
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
GSK amends commercial deal with Scynexis as antifungal recall drags into 2024
Fierce Pharma
When GSK laid out $90 million upfront to acquire rights to Scynexis' antifungal Brexafemme last spring, the British pharma threw a lifeline...
4 months ago
SCYNEXIS, Inc. (SCYX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek ...
WLNS 6 News
NEW YORK, NY / ACCESSWIRE / October 3, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of SCYNEXIS,...
3 days ago
SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why
Yahoo News New Zealand
SCYNEXIS' (SCYX) shares soar 134% year to date, owing to partnership with big wig GSK plc for the development of its antifungal tablet,...
4 days ago
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European ...
ABC4 Utah
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrata
3 days ago
Scynexis: Update Following Restructuring Of GSK Deal (NASDAQ:SCYX)
Seeking Alpha
Summary · Scynexis stock price has resumed the downtrend following a restructuring of the GSK deal associated with considerable reduction of...
1 month ago
Scynexis Allegedly Misrepresented Drug Contamination Recall Risk
Bloomberg Law News
Scynexis Inc.and its top executives allegedly misled investors about the contamination risks of a drug to treat fungal infections recalled...
5 months ago
SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly
Simply Wall Street
SCYNEXIS. SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections...
1 month ago
Contamination Risk Sparks a Recall of GSK, Scynexis Antifungal Drug
MedCity News
Contamination Risk Sparks a Recall of GSK, Scynexis Antifungal Drug. Scynexis said no adverse events or contamination problems have been...
7 months ago
SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why
Nasdaq
SCYNEXIS' SCYX shares have surged 133.6% year to date against the industry's 1.9% decline.
7 months ago
SCYX Stock Quote Price and Forecast
CNN
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of...
3 months ago